New Gestational Diabetes Guidelines 2026: What Changed

Each January, the American Diabetes Association publishes its updated Standards of Care in Diabetes—the most comprehensive clinical guidelines for diabetes management in the US. The 2026 edition, published January 2026, contains meaningful updates to the gestational diabetes chapter (Section 15: Management of Diabetes in Pregnancy). Here's what changed, what stayed the same, and what it means for your pregnancy.

How to Read These Guidelines

Before diving into the changes, it's helpful to understand how the ADA grades its recommendations:

• A: Clear evidence from well-conducted randomized controlled trials
• B: Supportive evidence from well-conducted cohort studies
• C: Supportive evidence from poorly controlled or uncontrolled studies
• E: Expert consensus or clinical experience

Higher grades reflect stronger evidence and carry more clinical weight.

Key Change 1: Expanded CGM Guidance in Pregnancy

This is the most significant structural change in the 2026 pregnancy chapter. In previous editions, CGM guidance for pregnancy was split between Section 7 (Diabetes Technology) and Section 15 (Pregnancy). In 2026:

• All CGM and AID (automated insulin delivery) guidance for pregnancy has been consolidated into Section 15
• The narrative has been updated to incorporate results from recent randomized controlled trials specifically examining CGM in gestational diabetes
• CGM is now explicitly acknowledged as beneficial for GD management, strengthening the medical necessity basis for insurance coverage

What this means for you: If you're seeking insurance coverage for a CGM for gestational diabetes, the 2026 ADA Standards provide stronger language to cite in a prior authorization or appeal letter.

Key Change 2: Blood Pressure Management Threshold

Recommendation 15.24 was modified: the blood pressure threshold for initiating or titrating antihypertensive therapy during pregnancy is now specifically set at 140/90 mmHg—rather than previous ambiguous language that allowed for clinical interpretation at lower thresholds.

Clinical significance: This aligns with recent randomized trial evidence showing that treating hypertension at this threshold reduces maternal cardiovascular complications without increasing adverse fetal outcomes. The previous uncertainty about when to treat borderline elevations in pregnancy has been resolved.

What this means for you: If you develop elevated blood pressure during pregnancy (a complication more common in women with GD), your provider has clearer guidance on when to initiate treatment. Preeclampsia screening and blood pressure monitoring are important components of GD care.

Key Change 3: Insulin Preparations in Pregnancy

The 2026 Standards include significantly expanded discussion of insulin preparations during pregnancy. Key updates include:

Rapid-Acting Insulin Analogs

Insulin lispro (Humalog) and insulin aspart (Novolog/Fiasp) have accumulated substantial evidence supporting their safety and efficacy during pregnancy. The 2026 guidelines include additional guidance on using these analogs for post-meal coverage, which is particularly relevant for gestational diabetes where post-meal spikes are the primary target.

Long-Acting Insulin

Insulin detemir (Levemir) has an FDA pregnancy indication (a rare distinction for insulin analogs). The 2026 guidance clarifies its use in pregnancy, including dosing considerations as insulin resistance increases throughout the third trimester.

Biosimilars

The expanding insulin biosimilar market now has products that are approved as interchangeable with brand-name insulins. The 2026 standards include language acknowledging the availability of biosimilars, which may offer cost savings for uninsured or underinsured pregnant women.

Key Change 4: Automated Insulin Delivery (AID) in Pregnancy

Automated insulin delivery—closed-loop systems that combine CGM with an insulin pump to automatically adjust insulin delivery—received expanded attention in the 2026 standards. While primarily relevant for type 1 diabetes in pregnancy, the guidance is evolving:

• The 2026 standards discuss AID use in type 1 pregnancy with updated evidence
• Ongoing clinical trials (including at UCSF) are expected to produce data by 2027 on AID during labor and delivery
• A note of caution: most current AID systems were designed for non-pregnant populations; pregnancy-specific targets and algorithms require modification

Key Change 5: Language and Framing

The 2026 ADA Standards continue a multi-year effort to incorporate person-first and inclusive language:

• "Pregnant women with diabetes" → "pregnant people with diabetes" or "pregnant individuals with diabetes"
• Recognition that not all people who become pregnant identify as women
• Emphasis on shared decision-making and respecting individual preferences

The guidelines also continue to emphasize that GD management decisions should be individualized, recognizing that different women have different values regarding treatment intensity, medication preference, and monitoring burden.

What Stayed the Same in 2026

Several key elements of gestational diabetes management were not changed, confirming their continued strength:

Glucose Targets

• Fasting: <95 mg/dL
• 1-hour post-meal: <140 mg/dL
• 2-hour post-meal: <120 mg/dL
• These targets remain the 2026 standard

Screening Timing

• 24-28 weeks for universal screening
• First visit testing for high-risk women (prior GD, BMI ≥30, prior macrosomic infant)

First-Line Treatment

• Medical nutrition therapy (diet modification) and physical activity remain first-line
• Insulin remains the preferred pharmacological treatment when lifestyle measures are insufficient
• Metformin is acknowledged as an option but with caveats about placental transfer and long-term offspring data

Postpartum Testing

• 75g OGTT at 4-12 weeks postpartum remains recommended for all women with GD
• Ongoing diabetes screening every 1-3 years for women with history of GD

What ACOG Says (2026)

The American College of Obstetricians and Gynecologists (ACOG) has its own gestational diabetes guidance. Key ACOG positions in 2026:

• ACOG continues to prefer the two-step screening approach (vs. ADA which gives more flexibility to one-step)
• Insulin remains ACOG's first-choice pharmacological treatment
• ACOG acknowledges growing CGM evidence but has not yet published updated CGM-specific guidance for GD
• An ACOG clinical practice update specifically addressing GD management technology is anticipated in 2026-2027

Putting the Guidelines Into Practice

The 2026 ADA Standards provide a framework, but individual care should be tailored. Here are the most actionable takeaways:

1. Ask about CGM: The 2026 guidelines provide the strongest language to date supporting CGM in GD—this is your opportunity to have that conversation if you haven't already
2. Know your glucose targets: The targets above are your benchmarks; not hitting them consistently is the threshold for stepping up to medication
3. Understand your blood pressure numbers: Blood pressure ≥140/90 mmHg warrants treatment; ask your provider to clarify their monitoring approach
4. Plan your postpartum testing: The 6-12 week OGTT after delivery is non-negotiable for long-term health—put it on your calendar now

For more on how these guidelines affect specific treatment decisions, see our articles on metformin vs. insulin for GD in 2026 and upcoming GD screening changes for 2027.

This content is for informational purposes only and is not medical advice. Always consult your healthcare provider or registered dietitian for personalized guidance.